Get started
Author

Davide Germano

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland
2010 · Manfred Beleut, Renuga Devi Rajaram, et al. · Proceedings of the National Academy of Sciences · 307
PDF
CD11b+ Monocytes Abrogate Th17 CD4+ T Cell-Mediated Experimental Autoimmune Myocarditis
2008 · Alan Valaperti, René R Marty, et al. · The Journal of Immunology · 137
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
2024 · Martin Dreyling, Nathan Hale Fowler, et al. · Blood · 102
Heart-Infiltrating Prominin-1 + /CD133 + Progenitor Cells Represent the Cellular Source of Transforming Growth Factor β–Mediated Cardiac Fibrosis in Experimental Autoimmune Myocarditis
2009 · Gabriela Kania, Przemyslaw Blyszczuk, et al. · Circulation Research · 92
PDF
Interferon-γ Regulates Idiopathic Pneumonia Syndrome, a Th17+CD4+ T-Cell–mediated Graft-versus-Host Disease
2008 · Nora Mauermann, Julia Burian, et al. · American Journal of Respiratory and Critical Care Medicine · 60
Prominin-1/CD133+ Lung Epithelial Progenitors Protect from Bleomycin-induced Pulmonary Fibrosis
2009 · Davide Germano, Przemyslaw Blyszczuk, et al. · American Journal of Respiratory and Critical Care Medicine · 41
Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment
2014 · Davide Germano, Marianne Uteng, et al. · Toxicology in Vitro · 26
Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
2022 · Martin Dreyling, Michael Dickinson, et al. · Blood · 20
Vaccination with Flt3L-induced CD8α+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis
2013 · Alan Valaperti, Mototsugu Nishii, et al. · Vaccine · 15
PDF
Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
2024 · Catherine Thieblemont, Martin Dreyling, et al. · Blood · 11
PDF
Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
2023 · Stephen J Schuster, Nathan Fowler, et al. · Blood · 11
Profibrotic potential of Prominin-1+epithelial progenitor cells in pulmonary fibrosis
2011 · Przemyslaw Blyszczuk, Davide Germano, et al. · Respiratory Research · 7
PDF
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
2022 · Claire Harrison, Florian H. Heidel, et al. · HemaSphere · 5
High Content Imaging Approaches for In Vitro Toxicology
2014 · Marianne Uteng, Davide Germano, et al. · Methods in pharmacology and toxicology · 5
Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
2024 · Stephen J. Schuster, Nathan H. Fowler, et al. · Transplantation and Cellular Therapy · 4
OA-12 Interim Phase 2 Study Results of Durcabtagene Autoleucel (PHE885), a T-Charge™ Manufactured BCMA-Directed CAR-T Cell Therapy in Patients (pts) with r/r Multiple Myeloma (RRMM)
2024 · Andrew Spencer, Marc-Steffen Raab, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
2023 · Nathan Fowler, Martin Dreyling, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
P157 Obecabtagene autoleucel, a CD19-targeting autologous chimeric antigen receptor T-cell therapy, in patients with severe, refractory systemic lupus erythematosus: Phase I CARLYSLE preliminary results
2026 · Maria Leandro, Ruth Pepper, et al. · Lara D. Veeken
LBS1:02 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel (obe-cel), in severe refractory systemic lupus erythematosus (srSLE): initial results from phase I CARLYSLE study
2026 · Maria Leandro, Ruth Pepper, et al.
PDF
Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results
2025 · Claire Roddie, Maria Leandro, et al. · Blood
IBCL-1066: ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
2025 · Catherine Thieblemont, Martin Dreyling, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1066 ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
2025 · Catherine Thieblemont, Martin Dreyling, et al. · Clinical Lymphoma Myeloma & Leukemia
Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow- Up
2024 · Stephen J. Schuster, Nathan Hale Fowler, et al. · Clinical Lymphoma Myeloma & Leukemia
IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
2024 · Stephen J. Schuster, Nathan Hale Fowler, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
2023 · Nathan Fowler, Martin Dreyling, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 34
Citation count: 846
H-index: 11
I10-index: 11
Year
Topic
Type